Your session is about to expire
← Back to Search
Pravastatin + Alkali Therapy for Polycystic Kidney Disease (ADPKD-SAT Trial)
ADPKD-SAT Trial Summary
This trial is testing a new treatment for ADPKD patients and will last one year.
ADPKD-SAT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ADPKD-SAT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have more than 500 milligrams of protein in your urine every day.You have had cancer in the past.You have had serious liver problems like liver failure, cirrhosis, or liver shock.You have a condition called metabolic acidosis.Your blood has a low level of bicarbonate.You have a recent heart condition, liver or muscle disease, or a past problem with fluid in your lungs.You have a condition that affects your kidneys, as determined by the doctor.You have high blood pressure that is not well controlled, swelling, or a serious heart condition according to the doctor's decision.Your kidney function, measured by GFR, is above a certain level.You have a history of kidney stones.Your Creatine Phospho Kinase (CPK) levels are higher than the normal range.You have a cerebral aneurysm that is not stable, as determined by the doctor.You have been diagnosed with ADPKD using a combination of ultrasound, genetic testing, and MRI if necessary.These ultrasound criteria are used to diagnose ADPKD in people from families with the disease, but where the specific genetic cause is not known.
- Group 1: ARM I: Control group
- Group 2: ARM II: PRAVASTATIN
- Group 3: ARM III: PRAV + Sodium Citrate
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are being recruited for this investigation?
"This investigation is no longer looking for participants. It first appeared on the 30th of January 2019 and its latest update was posted on the 24th of January 2022. If you are still searching for a suitable trial, there are currently 488 studies actively admitting patients with kidney diseases as well as 12 trials specifically related to ARM II: Pravastatin that require enrollees."
Have there been additional investigations involving ARM II: PRAVASTATIN?
"Currently, there are 12 studies in progress that evaluate the efficacy of ARM II: PRAVASTATIN with 3 trials currently undergoing Phase 3. Most sites are located within Los Angeles but 67 total clinical trial locations are engaging participants for this research."
Is ARM II: PRAVASTATIN generally well-tolerated by most individuals?
"Considering the information available, our team at Power estimates that ARM II: PRAVASTATIN is a safe treatment option with a score of 2 on this scale. This assessment was based off the Phase 2 trial's data which supports safety but not efficacy."
Are there still vacancies for participants in this clinical experiment?
"According to clinicaltrials.gov, this study is not presently accepting participants. The trial was initially announced on January 30th 2019 and its last update was posted on January 24th 2022. However, there are 500 other clinical trials actively recruiting right now."
What condition or disorder is ARM II: PRAVASTATIN primarily applied to?
"ARM II: PRAVASTATIN is typically employed to facilitate irrigation during surgeries, with additional applications in the management of cardiovascular disease (cvd), plasmapheresis, and catarrh."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger